Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 20/20 | 0.43 |
| ▸ | F11 | P03951 | 14/20 | 0.43 |
| ▸ | TPSB2 | P20231 | 9/20 | 0.43 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.43 |
| ▸ | PLG | P00747 | 3/20 | 0.43 |
| ▸ | PLAU | P00749 | 3/20 | 0.43 |
| ▸ | F7 | P08709 | 3/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.42 |
| ▸ | F9 | P00740 | 2/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852569 | 1.00 | CFD (0.43) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23219242 | 0.95 | CFD (0.47) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL29592619 | 0.95 | CFD (0.47) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL29852868 | 0.92 | CFD (0.47) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23218766 | 0.92 | CFD (0.47) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23219177 | 0.91 | CFD (0.43) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL29852544 | 0.91 | CFD (0.43) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23219083 | 0.86 | CFD (0.50) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL29592594 | 0.86 | CFD (0.50) | CFDF11TPSB2KLKB1PLG | |
| SCHEMBL23219142 | 0.86 | CFD (0.49) | CFDF11TPSB2KLKB1PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | ACADIA PHARMACEUTICALS INC. | 2016-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361275-A1 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | CFD 4300/4885F11 3972/4885TPSB2 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.